Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2018-07-19 Regulatory Filings
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Phase IIa study demonstrates favorable safety and tolerability profile for Biotest's monoclonal antibody BT-063 for treatment of systemic lupus erythematosus (SLE)
Regulatory Filings Classification · 100% confidence The document is a press release dated July 19, 2018, announcing the results of a Phase IIa clinical study for a drug candidate (BT-063) for Systemic Lupus Erythematosus (SLE). It details the study's primary endpoint (safety and tolerability) being met, mentions preliminary efficacy signs, and includes commentary from Key Opinion Leaders. This content is characteristic of a research update or clinical trial result announcement, which is best categorized as an 'Earnings Release' (ER) if it contains key financial/operational highlights, or potentially 'Regulatory Filings' (RNS) if it's a general news dissemination. However, given the focus on clinical trial results and the structure typical of an initial results announcement (not a full quarterly report or investor presentation), it aligns most closely with an Earnings Release (ER) which often includes significant operational milestones like successful trial phases, or it could be classified as a general Regulatory Filing (RNS) since it's a DGAP news item about research. Since there is no specific category for 'Clinical Trial Results', and it is a news announcement disseminating key operational performance data (even if not strictly financial earnings), 'ER' is a strong candidate, but 'RNS' is the safest fallback for general news dissemination via DGAP. Given the context of financial reporting databases, major operational news like this is often grouped with ERs or RNS. Since it is a specific announcement of a research update, and not a formal financial report (10-K, IR), I will lean towards RNS as the most appropriate general regulatory news category for non-standard financial disclosures, although ER is plausible if the database groups operational milestones there. Upon review, 'ER' is often used for any major period-end announcement containing key performance indicators, which clinical trial success is for a biotech. However, since the definitions provided do not explicitly cover clinical trial results, and this is a general news release disseminated via DGAP, 'RNS' (Regulatory Filings / General Regulatory Announcements) is the most appropriate catch-all for specific, non-standard disclosures.
2018-07-19 English
Datum:02.07.2018
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Biotest AG regarding the 'Gewinnverwendungsbeschluss' (resolution on the appropriation of profit) following the Annual General Meeting held on May 15, 2018. It explicitly details the dividend amount per share (EUR 0.04 for preferred shares and EUR 0.00 for common shares) and the total distribution amount. This fits the definition of a dividend declaration notice.
2018-07-02 German
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in voting rights percentages (crossing thresholds) by a shareholder (JO Hambro Capital Management Limited) in the issuer (Biotest AG). It references specific German securities law articles (WpHG, Sec. 33, 34, 38). This type of filing, which reports changes in significant share ownership levels crossing defined thresholds, directly corresponds to the definition of 'Major Shareholding Notification'.
2018-06-20 English
Biotest AG: Biotest AG opens third plasma collection centre in Czech Republi
Regulatory Filings Classification · 100% confidence The document is a short press release dated June 20, 2018, announcing that Biotest AG opened its third plasma collection center in the Czech Republic. It contains general company information, contact details, and is disseminated via DGAP News Service. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed report (IR, AR). Since it is a general corporate news announcement that doesn't fit into the highly specific categories (like DIRS, DIV, CAP, etc.), it falls best under the general regulatory announcement/news category, which is RNS (Regulatory Filings) as per the provided definitions, especially given the DGAP distribution context.
2018-06-20 English
Biotest AG: Large data analysis for DSA after lung transplantation confirms impressive therapy outcome with Pentaglobin(R)
Regulatory Filings Classification · 99% confidence The document is a press release dated May 29, 2018, announcing research update results concerning the therapy outcome with Pentaglobin(R) after lung transplantation. It uses keywords like 'DGAP-News', 'PRESS RELEASE', and details scientific findings and product information. This is not a formal regulatory filing like a 10-K, nor is it a transcript (CT) or a dividend notice (DIV). It is an announcement of research findings and product relevance, which fits best under a general regulatory/news announcement category. Since it is a specific news release about research and product data, and not a formal financial report (like IR or 10-K), the most appropriate general category for corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), as it is disseminated via the DGAP service, which explicitly mentions distributing 'Financial/Corporate News and Press Releases'. It is not an Earnings Release (ER) as it focuses on clinical data, not period financial results.
2018-05-29 English
Biotest AG: Efficacy and safety of Cytotect(R) CP was demonstrated in patients after stem cell transplantation
Legal Proceedings Report Classification · 99% confidence The document is titled 'News Details' and begins with a date and a headline about research findings ('Efficacy and safety of Cytotect(R) CP was demonstrated...'). It uses keywords like 'DGAP-News', 'PRESS RELEASE', and contains contact information for 'IR contact' and 'PR contact'. The content focuses on clinical study results and product information, which is typical of a press release announcing scientific or operational news, rather than a formal regulatory filing like a 10-K, IR, or ER. Since it is a general corporate announcement disseminated via a service like DGAP (which handles various news types), and it doesn't fit the specific categories like ER (Earnings Release), CT (Call Transcript), or SR (ESG), the most appropriate general category for a non-standard corporate news release is Regulatory Filings (RNS), which serves as a broad category for official announcements not covered elsewhere, especially when disseminated through regulatory news services.
2018-05-23 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.